Astellas Pharma, Inc. is currently ahead in the non-hormonal menopausal relief race but Bayer AG is coming up on the rails after reporting positive results from two late-stage trials for elinzanetant.
Bayer Hot On The Trail Of Astellas As Menopause Drug Flies In Phase III
Astellas’s fezolinetant is already on the market but Bayer is confident its non-hormonal menopause drug elinzanetant will be able to catch up on the back of demonstrating significant reductions in the frequency and severity of hot flashes in a couple of Phase III trials.
More from Women's Health
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.